Home › Research › Inflammation and the immune system
The Role of GFAP as a Marker of Astrocyte Activation in the Pathogenesis of Alzheimer's Dementia: A Literature Review
Komang Trisna Sumadewi. Health & Medical Sciences, 2025-12-09
Topic: Brain proteins, microglia and lab models
Plain-language summary
This study aims to comprehensively review the role of glial fibrillary acidic protein (GFAP) as a marker of astrocyte activation in Alzheimer's disease (AD). The research utilized a descriptive-qualitative literature review approach by analyzing various current scientific sources, including indexed international journal articles, research reports, and relevant academic documents published between 2015 and 2025. Data collection involved systematic literature search techniques, followed by analysis comprising theme identification, data reduction, concept categorization, and inductive conclusion drawing to obtain a holistic understanding of the phenomenon under study. The study results show that GFAP plays a crucial role as a sensitive biomarker for astrocyte activation that occurs since the preclinical phase of Alzheimer's, demonstrating a strong correlation with amyloid-beta accumulation and the neuroinflammatory process. In addition to its function in early detection, GFAP is also capable of predicting the conversion of mild cognitive impairment (MCI) to Alzheimer's dementia with high diagnostic accuracy. Despite limitations in specificity and measurement variation, the integration of GFAP with other biomarkers such as pTau, NfL, and YKL-40 significantly enhances diagnostic validity and its potential for therapy monitoring. In conclusion, GFAP is a multifunctional biomarker that not only deepens our understanding of the mechanisms of reactive astrocytosis in AD pathogenesis but also provides new directions for the development of non-invasive diagnostics and more precise therapeutic strategies in neurodegenerative diseases.
What this study adds
Evidence grade: Low
This literature review concludes that GFAP is a sensitive biomarker of astrocyte activation from the preclinical phase of Alzheimer's, correlating with amyloid-beta accumulation and neuroinflammation, and may help predict conversion from mild cognitive impairment. It is a review of biomarkers for detection and monitoring, not evidence of a treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sumadewi, K. T. (2025). The Role of GFAP as a Marker of Astrocyte Activation in the Pathogenesis of Alzheimer's Dementia: A Literature Review. Health & Medical Sciences. https://doi.org/10.47134/phms.v3i1.519
Vancouver
Sumadewi KT. The Role of GFAP as a Marker of Astrocyte Activation in the Pathogenesis of Alzheimer's Dementia: A Literature Review. Health & Medical Sciences. 2025. doi:10.47134/phms.v3i1.519.
BibTeX
@article{sumadewi2025-d3e2c144,
author = {Sumadewi, Komang Trisna},
title = {{The Role of GFAP as a Marker of Astrocyte Activation in the Pathogenesis of Alzheimer's Dementia: A Literature Review}},
journal = {Health \& Medical Sciences},
year = {2025},
doi = {10.47134/phms.v3i1.519},
url = {https://doi.org/10.47134/phms.v3i1.519}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The study results show that GFAP plays a crucial role as a sensitive biomarker for astrocyte activation that occurs since the preclinical phase of Alzheimer's, demonstrating a strong correlation with amyloid-beta accumulation and the neuroinflammatory process.
- Despite limitations in specificity and measurement variation, the integration of GFAP with other biomarkers such as pTau, NfL, and YKL-40 significantly enhances diagnostic validity and its potential for therapy monitoring.
- In conclusion, GFAP is a multifunctional biomarker that not only deepens our understanding of the mechanisms of reactive astrocytosis in AD pathogenesis but also provides new directions for the development of non-invasive diagnostics and more precise therapeutic strategies in neurodegenerative diseases.
Why it matters
This literature review concludes that GFAP is a sensitive biomarker of astrocyte activation from the preclinical phase of Alzheimer's, correlating with amyloid-beta accumulation and neuroinflammation, and may help predict conversion from mild cognitive impairment. It is a review of biomarkers for detection and monitoring, not evidence of a treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Health & Medical Sciences) |
| Journal's citation record | 0 / 4 | Health & Medical Sciences: journal h-index 2 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Komang Trisna Sumadewi: h-index 5 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Warmadewa University: institution h-index 49 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.